Minocycline in the treatment of patients with primary sclerosing cholangitis: Results of a pilot study

American Journal of Gastroenterology

Volumn 104, Issue 1, 2009, Pages 83-88

  Silveira, Marina G ^a   Torok, Natalie J ^b   Gossard, Andrea A ^a   Keach, Jill C ^a   Jorgensenrn, Roberta A ^a   Petzrn, Janice L ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MINOCYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELLULITIS; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FEVER; HUMAN; HYPERPIGMENTATION; JAUNDICE; MALE; NAUSEA; PHOTOSENSITIVITY; PILOT STUDY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK; SKIN TINGLING; TINNITUS; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; SCLEROSING CHOLANGITIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; MINOCYCLINE; PILOT PROJECTS; YOUNG ADULT;

EID: 60749089231     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2008.14     Document Type: Article

References (52)

1. Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325-32.
2. Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007;102: 1677-82.
3. Beuers U, Spengler U, Kruis W et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992;16:707-14.
4. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-5.
5. Mitchell SA, Bansi DS, Hunt N et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
6. Harnois DM, Angulo P, Jorgensen RA et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
7. Bambha K, Kim WR, Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364-9.
8. Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol 2008;14:3338-49.
9. Harada K, Kono N, Tsuneyama K et al. Cell-kinetic study of proliferating bile ductules in various hepatobiliary diseases. Liver 1998;18:277-84.
10. Floreani A, Guido M, Bortolami M et al. Relationship between apoptosis, tumour necrosis factor, and cell proliferation in chronic cholestasis. Dig Liver Dis 2001;33:570-5.
11. Tinmouth J, Lee M, Wanless IR et al. Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver 2002;22:228-34.
12. Wu CT, Eiserich JP, Ansari AA et al. Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. Hepatology 2003;38:1018-25.
13. Jaiswal M, LaRusso NF, Burgart LJ et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-90.
14. Jaiswal M, LaRusso NF, Shapiro RA et al. Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology 2001;120:190-9.
15. Stopper H, Moller M, Bommel HM et al. Cytotoxic vs. genotoxic effects of nitric oxide (NO). Toxicol Lett 1999;106:59-67.
16. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol 2004;287:G88-95.
17. Buttery LD, Springall DR, Andrade SP et al. Induction of nitric oxide synthase in the neo-vasculature of experimental tumours in mice. J Pathol 1993;171:311-9.
18. Facchetti F, Vermi W, Fiorentini S et al. Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. Am J Pathol 1999;154:145-52.
19. Scarabelli TM, Knight R, Stephanou A et al. Clinical implications of apoptosis in ischemic myocardium. Curr Probl Cardiol 2006;31:181-264.
20. Amin AR, Attur MG, Thakker GD et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996;93:14014-9.
21. Ledeboer A, Sloane EM, Milligan ED et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005;115:71-83.
22. Van den Bogert C, Kroon AM. Effects of oxytetracycline on in vivo proliferation and differentiation of erythroid and lymphoid cells in the rat. Clin Exp Immunol 1982;50:327-35.
23. Sewell KL, Breedveld F, Furrie E et al. The effect of minocycline in rat models of inflammatory arthritis: correlation of arthritis suppression with enhanced T cell calcium flux. Cell Immunol 1996;167: 195-204.
24. Yrjanheikki J, Tikka T, Keinanen R et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999;96: 13496-500.
25. Zhu S, Stavrovskaya IG, Drozda M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-8.
26. Van Den Bosch L, Tilkin P, Lemmens G et al. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002;13:1067-70.
27. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10: 268-78.
28. Chen M, Ona VO, Li M et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Hunting-ton disease. Nat Med 2000;6:797-801.
29. Wang X, Zhu S, Drozda M et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003;100:10483-7.
30. Wu DC, Jackson-Lewis V, Vila M et al. Blockade of microglial activation is neuroprotective in the l-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763-71.
31. Choi Y, Kim HS, Shin KY et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 2007;32:2393-404.
32. Yrjanheikki J, Keinanen R, Pellikka M et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95:15769-74.
33. Du Y, Ma Z, Lin S et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98:14669-74.
34. Scarabelli TM, Stephanou A, Pasini E et al. Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome c and smac/DIABLO. J Am Coll Cardiol 2004;43:865-74.
35. Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989;13 (Suppl 1): 43-9.
36. Kim WR, Therneau TM, Wiesner RH et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688-94.
37. Koga H, Sakisaka S, Ohishi M et al. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997;25:1077-84.
38. Sakisaka S, Koga H, Sasatomi K et al. Biliary secretion of endotoxin and pathogenesis of primary biliary cirrhosis. Yale J Biol Med 1997;70:403-8.
39. Rodrigues CM, Fan G, Ma X et al. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101:2790-9.
40. Rodrigues CM, Steer CJ. The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent. Expert Opin Investig Drugs 2001;10:1243-53.
41. Van Thiel DH, Carroll P, Abu-Elmagd K et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.
42. Talwalkar JA, Gossard AA, Keach JC et al. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007;27:451-3.
43. Farkkila M, Karvonen AL, Nurmi H et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40:1379-86.
44. Angulo P, Jorgensen RA, Kowdley KV et al. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci 2008;53:1716-20.
45. Silveira MG, Lindor KD. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. J Hepatol 2008;48:692-4.
46. Gordon PH, Moore DH, Gelinas DF et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 2004;62:1845-7.
47. Gordon PH, Moore DH, Miller RG et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045-53.
48. Matsuura T, Shimizu Y, Fujimoto H et al. Minocycline-related lupus. Lancet 1992;340:1553.
49. Gough A, Chapman S, Wagstaff K et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996;312:169-72.
50. Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996;134:693-5.
51. Angulo P, Larson DR, Therneau TM et al. Time course of histological progression in primary sclerosing cholangitis. Am J Gastroenterol 1999;94:3310-3.
52. Fong DG, Lindor KD. Future directions in the medical treatment of primary sclerosing cholangitis: the need for combination drug therapy. Am J Gastroenterol 2000;95:1861-2.